Concerning the performance of miR-486, it was as early as 2011 when Oh et al. reported that in the suppression of several pro-oncogenic traits, the inhibition of miR-486 further aggravated the proliferation of gastric cancer cells and promoted tumor progression by targeting OLFM4 [47]. This evidence concerns the gene OLFM4 and gastric cancer.